Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical benefit mechanism of intravenous alteplase in different subtypes of acute ischemic stroke
ChiCTR2600120870Phase 4Completed
- Sponsor
- People's Hospital of Bayingol Mongolian Autonomous Prefecture
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tissue-plasminogen activator in ischemic stroke, sponsored by People's Hospital of Bayingol Mongolian Autonomous Prefecture. Primary endpoints: 90±7-day Modified Rankin Scale (mRS) score, TOAST etiological classification and 1 more. Started Mar 2026; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2600120870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120870.